Cargando…

HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis

BACKGROUND: The national burden of human immunodeficiency virus treatment failure and associated factors in the Ethiopian context is required to provide evidence towards a renewed ambitious future goal. METHODS: We accessed Ethiopian Universities’ online repository library, Google Scholar, PubMed, W...

Descripción completa

Detalles Bibliográficos
Autores principales: Endalamaw, Aklilu, Mekonnen, Mengistu, Geremew, Demeke, Yehualashet, Fikadu Ambaw, Tesera, Hiwot, Habtewold, Tesfa Dejenie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971997/
https://www.ncbi.nlm.nih.gov/pubmed/31959136
http://dx.doi.org/10.1186/s12889-020-8160-8
_version_ 1783489831027867648
author Endalamaw, Aklilu
Mekonnen, Mengistu
Geremew, Demeke
Yehualashet, Fikadu Ambaw
Tesera, Hiwot
Habtewold, Tesfa Dejenie
author_facet Endalamaw, Aklilu
Mekonnen, Mengistu
Geremew, Demeke
Yehualashet, Fikadu Ambaw
Tesera, Hiwot
Habtewold, Tesfa Dejenie
author_sort Endalamaw, Aklilu
collection PubMed
description BACKGROUND: The national burden of human immunodeficiency virus treatment failure and associated factors in the Ethiopian context is required to provide evidence towards a renewed ambitious future goal. METHODS: We accessed Ethiopian Universities’ online repository library, Google Scholar, PubMed, Web of Science, and Scopus to get the research articles. We run I-squared statistics to see heterogeneity. Publication bias was checked by using Egger’s regression test. The pooled prevalence was estimated using the DerSimonian-Laird random-effects model. We employed the sensitivity analysis to see the presence of outlier result in the included studies. RESULTS: The overall human immunodeficiency treatment failure was 15.9% (95% confidence interval: 11.6–20.1%). Using immunological, virological, and clinical definition, human immunodeficiency treatment failure was 10.2% (95% confidence interval: 6.9–13.6%), 5.6% (95% confidence interval: 2.9–8.3%), and 6.3% (95% confidence interval: 4.6–8.0%), respectively. The pooled effects of World Health Organization clinical stage III/IV (Adjusted Odd Ratio = 1.9; 95% CI: 1.3–2.6), presence of opportunistic infections (Adjusted Odd Ratio = 1.8; 95% CI: 1.2–2.4), and poor adherence to highly active antiretroviral therapy (Adjusted Odd Ratio = 8.1; 95% CI: 4.3–11.8) on HIV treatment failure were estimated. CONCLUSIONS: Human immunodeficiency virus treatment failure in Ethiopia found to be high. Being on advanced clinical stage, presence of opportunistic infections, and poor adherence to highly active antiretroviral therapy were the contributing factors of human immunodeficiency virus treatment failure. Human immunodeficiency virus intervention programs need to address the specified contributing factors of human immunodeficiency virus treatment failure. Behavioral intervention to prevent treatment interruption is required to sustain human immunodeficiency virus treatment adherence. PROTOCOL REGISTRATION: It has been registered in the PROSPERO database with a registration number of CRD42018100254.
format Online
Article
Text
id pubmed-6971997
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69719972020-01-27 HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis Endalamaw, Aklilu Mekonnen, Mengistu Geremew, Demeke Yehualashet, Fikadu Ambaw Tesera, Hiwot Habtewold, Tesfa Dejenie BMC Public Health Research Article BACKGROUND: The national burden of human immunodeficiency virus treatment failure and associated factors in the Ethiopian context is required to provide evidence towards a renewed ambitious future goal. METHODS: We accessed Ethiopian Universities’ online repository library, Google Scholar, PubMed, Web of Science, and Scopus to get the research articles. We run I-squared statistics to see heterogeneity. Publication bias was checked by using Egger’s regression test. The pooled prevalence was estimated using the DerSimonian-Laird random-effects model. We employed the sensitivity analysis to see the presence of outlier result in the included studies. RESULTS: The overall human immunodeficiency treatment failure was 15.9% (95% confidence interval: 11.6–20.1%). Using immunological, virological, and clinical definition, human immunodeficiency treatment failure was 10.2% (95% confidence interval: 6.9–13.6%), 5.6% (95% confidence interval: 2.9–8.3%), and 6.3% (95% confidence interval: 4.6–8.0%), respectively. The pooled effects of World Health Organization clinical stage III/IV (Adjusted Odd Ratio = 1.9; 95% CI: 1.3–2.6), presence of opportunistic infections (Adjusted Odd Ratio = 1.8; 95% CI: 1.2–2.4), and poor adherence to highly active antiretroviral therapy (Adjusted Odd Ratio = 8.1; 95% CI: 4.3–11.8) on HIV treatment failure were estimated. CONCLUSIONS: Human immunodeficiency virus treatment failure in Ethiopia found to be high. Being on advanced clinical stage, presence of opportunistic infections, and poor adherence to highly active antiretroviral therapy were the contributing factors of human immunodeficiency virus treatment failure. Human immunodeficiency virus intervention programs need to address the specified contributing factors of human immunodeficiency virus treatment failure. Behavioral intervention to prevent treatment interruption is required to sustain human immunodeficiency virus treatment adherence. PROTOCOL REGISTRATION: It has been registered in the PROSPERO database with a registration number of CRD42018100254. BioMed Central 2020-01-20 /pmc/articles/PMC6971997/ /pubmed/31959136 http://dx.doi.org/10.1186/s12889-020-8160-8 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Endalamaw, Aklilu
Mekonnen, Mengistu
Geremew, Demeke
Yehualashet, Fikadu Ambaw
Tesera, Hiwot
Habtewold, Tesfa Dejenie
HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis
title HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis
title_full HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis
title_fullStr HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis
title_full_unstemmed HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis
title_short HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis
title_sort hiv/aids treatment failure and associated factors in ethiopia: meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971997/
https://www.ncbi.nlm.nih.gov/pubmed/31959136
http://dx.doi.org/10.1186/s12889-020-8160-8
work_keys_str_mv AT endalamawaklilu hivaidstreatmentfailureandassociatedfactorsinethiopiametaanalysis
AT mekonnenmengistu hivaidstreatmentfailureandassociatedfactorsinethiopiametaanalysis
AT geremewdemeke hivaidstreatmentfailureandassociatedfactorsinethiopiametaanalysis
AT yehualashetfikaduambaw hivaidstreatmentfailureandassociatedfactorsinethiopiametaanalysis
AT teserahiwot hivaidstreatmentfailureandassociatedfactorsinethiopiametaanalysis
AT habtewoldtesfadejenie hivaidstreatmentfailureandassociatedfactorsinethiopiametaanalysis